Cargando…
PSUN190 Is Euglycemic Diabetic Ketoacidosis an Underrecognized Risk of SGLT2 Inhibitor Utilization?
INTRODUCTION: Sodium-glucose cotransporter-2 (SGLT2) inhibitors were first approved by the FDA in March of 2013 as a promising new medication in the treatment of Type II diabetes mellitus. The mechanism of action of the Sodium-glucose cotransporter-2 is in the convoluted tubule of the nephron and wh...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624814/ http://dx.doi.org/10.1210/jendso/bvac150.780 |